We confirmed the effectiveness of canakinumab on modulating the concentrations of alarmins (MRP 8/14 and S100A12), IL-1RA, IL-18 and IL-6 in patients with AOSD with the strongest association with response rate. This evidence concerns the gene IL18 and adult-onset Still disease.